MA54411B1 - Compositions contenant de l'ibrutinib - Google Patents
Compositions contenant de l'ibrutinibInfo
- Publication number
- MA54411B1 MA54411B1 MA54411A MA54411A MA54411B1 MA 54411 B1 MA54411 B1 MA 54411B1 MA 54411 A MA54411 A MA 54411A MA 54411 A MA54411 A MA 54411A MA 54411 B1 MA54411 B1 MA 54411B1
- Authority
- MA
- Morocco
- Prior art keywords
- sodium
- lymphoma
- compositions
- ibrutinib
- metabolite
- Prior art date
Links
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title abstract 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title abstract 4
- 229960001507 ibrutinib Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 abstract 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004376 Sucralose Substances 0.000 abstract 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 229960002303 citric acid monohydrate Drugs 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 abstract 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 abstract 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 235000019408 sucralose Nutrition 0.000 abstract 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143659P | 2015-04-06 | 2015-04-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54411A MA54411A (fr) | 2021-10-13 |
| MA54411B1 true MA54411B1 (fr) | 2023-11-30 |
Family
ID=55806788
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54411A MA54411B1 (fr) | 2015-04-06 | 2016-04-06 | Compositions contenant de l'ibrutinib |
| MA041901A MA41901A (fr) | 2015-04-06 | 2016-04-06 | Compositions contenant de l'ibrutinib |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041901A MA41901A (fr) | 2015-04-06 | 2016-04-06 | Compositions contenant de l'ibrutinib |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US20160287594A1 (enExample) |
| EP (3) | EP3892302B8 (enExample) |
| JP (4) | JP2018513852A (enExample) |
| KR (2) | KR20240013859A (enExample) |
| CN (2) | CN107530293A (enExample) |
| AU (4) | AU2016246669B2 (enExample) |
| CA (1) | CA2981601A1 (enExample) |
| CL (1) | CL2017002512A1 (enExample) |
| DK (1) | DK3892302T3 (enExample) |
| EA (1) | EA033992B1 (enExample) |
| ES (1) | ES2964472T3 (enExample) |
| FI (1) | FI3892302T3 (enExample) |
| HK (1) | HK1250925A1 (enExample) |
| HR (1) | HRP20231207T1 (enExample) |
| HU (1) | HUE063751T2 (enExample) |
| IL (2) | IL295941A (enExample) |
| LT (1) | LT3892302T (enExample) |
| MA (2) | MA54411B1 (enExample) |
| MD (1) | MD3892302T2 (enExample) |
| MX (2) | MX2017012822A (enExample) |
| PH (1) | PH12017501811A1 (enExample) |
| PL (1) | PL3892302T3 (enExample) |
| PT (1) | PT3892302T (enExample) |
| RS (1) | RS64653B1 (enExample) |
| SG (2) | SG11201707989PA (enExample) |
| SI (1) | SI3892302T1 (enExample) |
| SM (1) | SMT202300422T1 (enExample) |
| UA (1) | UA125681C2 (enExample) |
| WO (1) | WO2016164404A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| EP3892302B8 (en) | 2015-04-06 | 2023-10-18 | Janssen Pharmaceutica NV | Compositions containing ibrutinib |
| CN109790121B (zh) | 2016-10-06 | 2024-01-05 | 詹森药业有限公司 | 用于制备btk抑制剂的方法和中间体 |
| WO2018167628A1 (en) | 2017-03-13 | 2018-09-20 | Ftf Pharma Private Limited | Pharmaceutical composition of oral suspension of immunosuppressive agents |
| CN108653231A (zh) * | 2017-04-01 | 2018-10-16 | 北京赛林泰医药技术有限公司 | 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法 |
| CN107014943B (zh) * | 2017-06-07 | 2018-08-21 | 福建省微生物研究所 | 一种依鲁替尼对映异构体的检测方法 |
| WO2019038584A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| US11576917B2 (en) | 2018-01-20 | 2023-02-14 | Natco Pharma Limited | Pharmaceutical compositions comprising Ibrutinib |
| KR20190122561A (ko) * | 2018-04-21 | 2019-10-30 | 류형준 | 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물 |
| KR102844084B1 (ko) * | 2018-06-15 | 2025-08-07 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| GB2591396B (en) | 2018-08-18 | 2023-06-07 | Ftf Pharma Private Ltd | Pharmaceutical suspension for oral dosage |
| US12083222B2 (en) | 2018-08-18 | 2024-09-10 | Oncosol Limited | Chemotherapeutic pharmaceutical suspension for oral dosage |
| KR102198502B1 (ko) * | 2018-09-16 | 2021-01-05 | 류형준 | 인체의 림프순환 개선을 위한 식품 조성물 |
| JP2022513666A (ja) * | 2018-11-30 | 2022-02-09 | ヤンセン バイオテツク，インコーポレーテツド | 濾胞性リンパ腫の治療方法 |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| KR102251435B1 (ko) * | 2020-11-09 | 2021-05-11 | 류형준 | 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물 |
| US11433072B1 (en) * | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| TN2023000295A1 (en) * | 2021-06-10 | 2025-07-02 | Hikma Pharmaceuticals Usa Inc | Oral dosage forms of ibrutinib |
| CN117064862B (zh) * | 2023-04-10 | 2025-12-19 | 山东新时代药业有限公司 | 一种伊布替尼肠溶片及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK607188A (da) | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| DE10201304A1 (de) | 2002-01-15 | 2003-07-31 | Infineon Technologies Ag | Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren |
| WO2006116596A2 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compostions containing same |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| US8003309B2 (en) | 2008-01-16 | 2011-08-23 | International Business Machines Corporation | Photoresist compositions and methods of use in high index immersion lithography |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| WO2014142678A1 (en) | 2013-03-14 | 2014-09-18 | Fisher & Paykel Healthcare Limited | Catheter mount with suction port |
| CN104119350B (zh) | 2013-04-28 | 2017-04-12 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| CA2920821A1 (en) * | 2013-08-12 | 2015-02-19 | The Yokohama Rubber Co., Ltd. | Primer composition |
| CA2920534A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| WO2015140709A1 (en) | 2014-03-19 | 2015-09-24 | Novartis Ag | Solid pharmaceutical dosage forms |
| BR112017001677A2 (pt) | 2014-08-01 | 2018-07-17 | Pharmacyclics Llc | biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
| CN104407067B (zh) * | 2014-11-17 | 2016-01-20 | 广东东阳光药业有限公司 | 依鲁替尼及其异构体的检测方法 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| EP3892302B8 (en) | 2015-04-06 | 2023-10-18 | Janssen Pharmaceutica NV | Compositions containing ibrutinib |
| MX2018014577A (es) | 2016-05-27 | 2019-05-20 | Tg Therapeutics Inc | Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b. |
-
2016
- 2016-04-06 EP EP21161828.5A patent/EP3892302B8/en active Active
- 2016-04-06 CN CN201680020815.3A patent/CN107530293A/zh active Pending
- 2016-04-06 EP EP16718083.5A patent/EP3280446A1/en not_active Withdrawn
- 2016-04-06 US US15/092,195 patent/US20160287594A1/en not_active Abandoned
- 2016-04-06 AU AU2016246669A patent/AU2016246669B2/en active Active
- 2016-04-06 SG SG11201707989PA patent/SG11201707989PA/en unknown
- 2016-04-06 JP JP2017552451A patent/JP2018513852A/ja not_active Withdrawn
- 2016-04-06 SI SI201631752T patent/SI3892302T1/sl unknown
- 2016-04-06 LT LTEP21161828.5T patent/LT3892302T/lt unknown
- 2016-04-06 SG SG10202103458QA patent/SG10202103458QA/en unknown
- 2016-04-06 WO PCT/US2016/026134 patent/WO2016164404A1/en not_active Ceased
- 2016-04-06 RS RS20230820A patent/RS64653B1/sr unknown
- 2016-04-06 PT PT211618285T patent/PT3892302T/pt unknown
- 2016-04-06 PL PL21161828.5T patent/PL3892302T3/pl unknown
- 2016-04-06 MA MA54411A patent/MA54411B1/fr unknown
- 2016-04-06 ES ES21161828T patent/ES2964472T3/es active Active
- 2016-04-06 EA EA201792224A patent/EA033992B1/ru unknown
- 2016-04-06 IL IL295941A patent/IL295941A/en unknown
- 2016-04-06 FI FIEP21161828.5T patent/FI3892302T3/fi active
- 2016-04-06 EP EP23194083.4A patent/EP4272835A3/en active Pending
- 2016-04-06 KR KR1020247002178A patent/KR20240013859A/ko not_active Ceased
- 2016-04-06 UA UAA201710677A patent/UA125681C2/uk unknown
- 2016-04-06 MA MA041901A patent/MA41901A/fr unknown
- 2016-04-06 CA CA2981601A patent/CA2981601A1/en active Pending
- 2016-04-06 HK HK18110381.6A patent/HK1250925A1/zh unknown
- 2016-04-06 KR KR1020177031664A patent/KR102632745B1/ko active Active
- 2016-04-06 MD MDE20211011T patent/MD3892302T2/ro unknown
- 2016-04-06 DK DK21161828.5T patent/DK3892302T3/da active
- 2016-04-06 HR HRP20231207TT patent/HRP20231207T1/hr unknown
- 2016-04-06 HU HUE21161828A patent/HUE063751T2/hu unknown
- 2016-04-06 SM SM20230422T patent/SMT202300422T1/it unknown
- 2016-04-06 CN CN202110822502.2A patent/CN113546054A/zh active Pending
- 2016-04-06 MX MX2017012822A patent/MX2017012822A/es unknown
-
2017
- 2017-05-23 US US15/602,989 patent/US20170252344A1/en not_active Abandoned
- 2017-09-26 IL IL254695A patent/IL254695B2/en unknown
- 2017-10-02 PH PH12017501811A patent/PH12017501811A1/en unknown
- 2017-10-05 MX MX2021015250A patent/MX2021015250A/es unknown
- 2017-10-05 CL CL2017002512A patent/CL2017002512A1/es unknown
-
2019
- 2019-12-10 US US16/708,929 patent/US20200171036A1/en not_active Abandoned
-
2021
- 2021-10-14 AU AU2021250925A patent/AU2021250925B2/en active Active
- 2021-11-08 JP JP2021181761A patent/JP7438178B2/ja active Active
-
2022
- 2022-03-29 US US17/706,783 patent/US20220211713A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/304,685 patent/US12364698B2/en active Active
- 2023-11-13 JP JP2023193108A patent/JP2024026087A/ja active Pending
-
2024
- 2024-02-12 AU AU2024200883A patent/AU2024200883A1/en not_active Abandoned
-
2025
- 2025-06-18 US US19/242,019 patent/US20260048055A1/en active Pending
-
2026
- 2026-02-11 AU AU2026200996A patent/AU2026200996A1/en active Pending
- 2026-03-25 JP JP2026050359A patent/JP2026116969A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4272835A3 (en) | Compositions containing ibrutinib | |
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA37610B1 (fr) | Formulations de testostérone proliposomales | |
| MA42292A (fr) | Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b | |
| JP2018513852A5 (enExample) | ||
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA38399B2 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| MA44206A (fr) | Comprimé orodispersible comprenant estetrol | |
| EP2548552A3 (en) | Titration package for 1-amino-alkylcylohexanes | |
| MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MA31706B1 (fr) | Formulations galéniques de composés organiques | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
| MA30779B1 (fr) | Comprimes pediatriques de capecitabine | |
| EP2796450A4 (en) | 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MX2021013488A (es) | Formulaciones liquidas de dosis oral de metilnaltrexona. | |
| MA35088B1 (fr) | Formulation comprenant un dérivé de phénylaminopyrimidine en tant qu'agent actif | |
| MA44079B1 (fr) | Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine | |
| MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
| MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. |